Dernières nouvelles pour Ascendis Pharma (NASDAQ:ASND) Stock

Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma AS

On Monday, Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) granted Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) an <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41709477/ascendis-pharma-and-novo-nordisk-sign-collaboration-for-development-and-commercialization-of-trans" rel="noreferrer noopener">exclusive worldwide license</a>.
The pact will focus on the TransCon technology platform to develop, manufacture, and commercialize Novo Nordisk proprietary products for metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license for cardiovascular diseases.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40882593/ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year" rel="noreferrer noopener">Ascendis Pharma&#8217;s Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year</a>
The agreement includes provisions requiring certain TransCon technology-based products to be identified and advanced in metabolic diseases to maintain exclusivity in the field and additional provisions for cardiovascular diseases.
Under the terms of the agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas.
The lead program in the collaboration is a once-monthly GLP-1 receptor agonist product candidate that will initially target obesity and type 2 diabetes.
Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program.
In addition, Ascendis will be eligible to receive sales-based milestone payments and tiered royalties on global net sales.
For each additional metabolic or cardiovascular disease product candidate, Ascendis will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.
Ascendis will conduct early development of TransCon product candidates in collaboration.
Novo Nordisk will be responsible for these early development costs, clinical development, regulatory, commercial manufacturing, and commercialization.
&#8220;The agreement with Novo Nordisk reflects our Vision 2030 to create value in additional large therapeutic areas outside endocrinology rare disease through collaborations with established global leaders,&#8221; said Jan Mikkelsen, Ascendis Pharma&#8217;s President and CEO.
&#8220;We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases,&#8221; said Brian Vandahl, Senior Vice President of Global Research Technologies at Novo Nordisk.
The transaction is expected to close before the end of 2024.
Price Action: At the last check on Monday, ASND stock was up 1.91% at $127.67, and NVO stock was down 1.61% at $110.14.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41720697/totalenergies-bolsters-lng-presence-in-china-with-15-year-supply-deal-details" target="_blank" rel="noreferrer noopener">TotalEnergies Bolsters LNG Presence In China With 15-Year Supply Deal: Details</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Biotech

Large Cap

News

Health Care

Contracts

Movers

General

ASND

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 19.45% on an annualized basis producing an average annual return of 31.06%. Currently, Ascendis Pharma has a market capitalization of $7.49 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $5,581.08 today based on a price of $125.28 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730739621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and maintains $170 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $170 Price Target

Ascendis has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.
In exchange for the license, Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program.&nbsp;
In addition, Ascendis will be eligible to receive sales-based milestone payments and tiered royalties on global net sales. For each additional metabolic or cardiovascular disease product candidate, Ascendis will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.
The closing of this transaction is subject to receipt of applicable regulatory approvals and the parties are seeking to close before the end of 2024.
 &nbsp;

Ascendis Pharma, Novo Nordisk Partner For Development, Commercialization Of TransCon Technology-Based Products In Metabolic, Cardiovascular Diseases; Ascendis To Be Eligible To Receive Payments Of Up To $285M For Lead Program

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) <a href="https://www.benzinga.com/earnings">reported third-quarter</a> adjusted EPS of 91 cents, almost double the 46 cents reported a year ago, beating the consensus of 52 cents.
The company reported sales of $745.74 million, beating the consensus of $700.14 million. Sales increased 28%, driven by strong VOXZOGO contributions from new <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41610287/biomarin-announces-28-yy-total-revenue-growth-in-the-third-quarter-and-increase-in-full-year-2024-" rel="noreferrer noopener">patient starts in all regions</a>.
In the quarter, revenues from BioMarin&#8217;s Enzyme Therapies (Vimizim, Naglazyme, Aldurazyme, Brineura, and Palynziq) increased 27% year over year.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41033938/biomarin-stands-firm-on-2027-revenue-target-amid-ascendis-competition-goldman-sachs" rel="noreferrer noopener">BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish</a>
Guidance: BioMarin reaffirmed its long-term guidance and outlook, targeting around $4 billion in revenues in 2027.
The company expects a 40% adjusted operating margin starting in 2026 and growing to the low-to mid-40% range over time.
William Blair has downgraded <a target="_blank" href="https://www.benzinga.com/quote/BMRN/analyst-ratings" rel="noreferrer noopener">BioMarin to a Market Perform</a>.
The analyst adds, &#8220;We believe the company&#8217;s current valuation adequately reflects revenue estimates for the company&#8217;s commercial portfolio, and we do not think its clinical pipeline will be a source of significant value creation in the near term.&#8221;
William Blair models 2024 and 2025 revenue of $2.8 billion and $3.1 billion, respectively.
Voxzogo sales increased 54% to $190 million in the third quarter. The analyst says Voxzogo remains the company&#8217;s key topline growth driver, but the threat of competition could erode its revenue growth and market share.
Last month, Ascendis Pharma A/S&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) released topline data from a trial in achondroplasia, showing its long-acting CNP, navepegritide, could potentially deliver similar efficacy as Voxzogo but with a more attractive once-weekly dosing.
Although Voxzogo&#8217;s label might expand, William Blair does not anticipate a significant increase in the total addressable patient population until 2030.
Despite BioMarin&#8217;s strong pipeline, the analyst does not consider data readouts from its early-stage programs over the next year as significant value drivers.
Only two programs are expected to contribute to BioMarin&#8217;s top line through label expansions by 2027: Palynziq for adolescent Phenylketonuria (PKU) patients and Voxzogo for Hypochondroplasia&nbsp;(HCH).
Analyst Reaction:
<ul>
<li>Baird maintains Biomarin and lowers the price target from $72 to $65.</li>
<li>UBS reaffirms the Buy rating, raising the price target from $104 to $106.</li>
<li>Evercore ISI maintains Biomarin with an Outperform rating, lowering the price target from $115 to $105.</li>
<li>RBC Capital reiterates Biomarin with a Sector Perform and price target of $80.</li>
</ul>
Price Action: BMRN stock is down 3.1% at $67.74 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41629194/wingstop-q3-eps-misses-as-chicken-wing-costs-bite-strong-sales-growth-aggressive-expansion-plans-mo" target="_blank" rel="noreferrer noopener">Wingstop Q3: EPS Misses As Chicken Wing Costs Bite, Strong Sales Growth, Aggressive Expansion Plans &amp; More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Earnings

Guidance

Downgrades

BMRN

BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and lowers the price target from $180 to $174.

JP Morgan Maintains Overweight on Ascendis Pharma, Lowers Price Target to $174

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and raises the price target from $157 to $160.

TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $160

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 10 years by 39.55% on an annualized basis producing an average annual return of 51.37%. Currently, Ascendis Pharma has a market capitalization of $7.92 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 10 years ago, it would be worth $6,501.23 today based on a price of $132.47 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728417613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years

Everybody loves finding a bargain or getting a good deal, and it&#39;s no different when it comes to stocks. One of the most popular technical indicators for helping investors find these is the Relative Strength Index (RSI).&nbsp;
Every stock has one. It works by considering a stock&#39;s recent performance over the past 14 trading days and spitting out a number ranging from 0 to 100. An RSI reading of more than 70 suggests extremely overbought conditions, while a reading below 30 suggests the opposite. The more extreme the reading, the more extreme the suggested condition of the stock.&nbsp;
With the benchmark S&amp;P 500 index back up around all-time highs since the Fed confirmed it was cutting rates, investor sentiment is clearly still bullish. This makes it all the more interesting when you then see a stock selling hard. Any indication that the selling might be verging on overdone or that the bears are running out of steam can mean a quick bounce is in store. With that in mind, here are three stocks with RSI readings that suggest they&#39;re extremely oversold.&nbsp;&nbsp;
<h2>Wall Street Sees Opportunity in Humana&#39;s Oversold Condition</h2>
Humana Inc., the for-profit health insurance company, has been selling off for over two years. Considering the gains the broader market has registered in this timeframe, the Louisville-based company&#39;s underperformance will be a bitter pill.&nbsp;
Its shares were down more than 50% in that timeframe and went back into trading at 2017 levels. Despite beating analyst expectations in its Q2 earnings report over the summer, things have only gotten worse, with yesterday&#39;s negative update on membership numbers the latest headwind to deal with.&nbsp;
At one point yesterday, Humana shares were trading more than 30% off where they closed last week, resulting in an RSI reading of just 15. This is the stock&#39;s lowest reading in 16 years, a fact that hasn&#39;t gone unnoticed by Wall Street. This isn&#39;t a company to be holding for the long run, but the strong buying action all the way into yesterday&#39;s close suggests there&#39;s a fast and hard bounce kicking off that can be capitalized on.&nbsp;
<h2>Elevance Health&#39;s Oversold RSI Suggests Significant Upside Potential</h2>
Though not quite as extreme as Humana&#39;s, Elevance Health, Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/elv#NYSE">ELV</a>)&#39;s RSI reading of 26 does suggest the Indianapolis health insurer is extremely oversold.
Compared to Humana, however, there&#39;s a lot more to like about Elevance for the long term, not least the fact that the company was trading at all-time highs as recently as July.&nbsp;
While its stock has been softening since the first week of September, it gapped down at yesterday&#39;s open. This was almost certainly off the back of Humana&#39;s negative update, and already, it&#39;s being treated as an entry opportunity.&nbsp;
Elevance shares gained into Wednesday&#39;s close and were trading up in Thursday&#39;s pre-market session. Considering how low their RSI still is, however, there&#39;s clearly a ton more room for them to run.&nbsp;
<h2>BioMarin Stock Holds Firm After Sharp Decline, Bulls Eyeing Comeback</h2>
BioMarin Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmrn#NASDAQ">BMRN</a>) shares of biotech stock have been effectively range-bound since 2016.
Pharmaceutical companies often experience this, as they depend heavily on positive results from drug and treatment trials rather than more standard fundamental performance for their stock&#39;s direction.&nbsp;
September gave a good example of just how exposed these companies can be, even to updates from their peers in this regard. When positive results from an Ascendis Pharma A/S (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asnd#NASDAQ">ASND</a>) trial were announced, they were seen as a threat to BioMarins&#39; ongoing Voxzogo trials.&nbsp;
BioMarin shares lost more than 20% immediately, but the bears could not take it any lower. They have been consolidating since then, which suggests the bulls could soon be back in control. With BioMarin&#39;s RSI still only at 26, though, while its MACD edges closer to a bullish crossover, this one has all the feel of a comeback rally.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-oversold-stocks-with-big-rsi-rebound-potential/">3 Oversold Stocks with Big RSI Rebound Potential</a>&quot; first appeared on MarketBeat.

Mid Cap

Technicals

Markets

Insurance

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

3 Oversold Stocks with Big RSI Rebound Potential

Ascendis Pharma Presents 3-Year Data At ASBMR 2024 Showing Long-Term Treatment With TransCon PTH Normalizes Bone Remodeling In Adults With Hypoparathyroidism

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has fallen 10.56% since its last report. The company recently reported that it has 3.34 million shares sold short, which is 7.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727362821_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 5.70%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Ascendis Pharma's Recent Short Interest

Last week, Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40882593/ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year" rel="noreferrer noopener">disproportionate short stature</a>.
Goldman Sachs hosted an investor meeting with BioMarin Pharmaceutical Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) Alexander Hardy (President and CEO) and Brian Mueller (EVP, CFO).
They reiterated financial guidance after reviewing their assumptions around Voxzogo competition post-Ascendis Pharma's better-than-expected Phase 3 achondroplasia data.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40200109/rare-disease-focused-biomarin-narrows-sales-focus-cuts-cost-for-hemophilia-a-gene-t" rel="noreferrer noopener">Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance</a>.
The analyst notes that management believes a U.S./EU launch by Ascendis Pharma could violate its C-type natriuretic <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40885653/despite-being-first-mover-biomarins-voxzogo-for-dwarfism-to-face-pressure-from-asce" rel="noreferrer noopener">peptide (CNP) patents</a>.
However, excluding this concern, the company still expects to reach approximately $4 billion in total revenue for fiscal year 2027, driven by growing Voxzogo adoption in the U.S., aided by its broad label without lower age restrictions, which could provide a competitive edge over Ascendis Pharma.
The company is targeting an adjusted operating margin of low-to-mid 40% (starting at 40% in 2026).
The new structure, announced at an investor event,&nbsp;<a target="_blank" href="https://investorday.biomarin.com/static-files/95c517e2-36ee-4427-9278-2d87cc4c1460" rel="noreferrer noopener">covers</a> three key business units: skeletal conditions, enzyme therapies, and Roctavian—its <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40731810/biomarin-restructures-outlines-roadmap-to-4b-revenues-by-2027" rel="noreferrer noopener">hemophilia A gene therapy</a>.
BioMarin has been implementing a $500 million "cost transformation program"&nbsp;to contribute to non-GAAP operating margin targets set for 2026 and beyond.
Goldman Analyst writes, "We also see external business development as a potential source of upside and diversification beyond BioMarin's guidance. Nonetheless, we note continued investor debate on the outlook given increasing competitive pressure on BioMarin's key growth driver."
The analyst maintains a Buy rating with a <a target="_blank" href="https://www.benzinga.com/quote/BMRN/analyst-ratings" rel="noreferrer noopener">price target of $139</a>.
Price Action: BMRN stock is down 0.57% at $69.09 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41029168/meta-connect-leaks-reveal-affordable-quest-3s-batman-game-bundle-report" target="_blank" rel="noreferrer noopener">Meta Connect Leaks Reveal Affordable Quest 3S, Batman Game Bundle: Report</a>.</li>
</ul>

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 10 years by 42.38% on an annualized basis producing an average annual return of 53.62%. Currently, Ascendis Pharma has a market capitalization of $8.60 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 10 years ago, it would be worth $6,965.87 today based on a price of $144.89 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727213417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and raises the price target from $175 to $191.

B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $191

This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40937291/bank-stocks-hit-inflection-point-after-feds-50-basis-point-cut-analyst-reveal-top-p" rel="noreferrer noopener">industrial, machinery, and financial sectors</a>.
These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) shares rocketed 50.19% after the company announced topline data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-<a href="https://www.benzinga.com//node/40940696" target="_blank" rel="noreferrer noopener">HCM trial in patients with obstructive HCM</a>.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) stock gained 28.36% after <a href="https://www.benzinga.com//node/40884021" target="_blank" rel="noreferrer noopener">reportedly considering a sale</a>.</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) shares upped 27.06%. The company's subsidiary Bausch + Lomb Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) <a href="https://www.benzinga.com//node/40884021" target="_blank" rel="noreferrer noopener">is reportedly considering a sale</a>.</li>
<li>Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) stock gained 26.87% last week after the company announced <a href="https://www.benzinga.com//node/40882593" target="_blank" rel="noreferrer noopener">topline data from</a> its pivotal approach trial of a rare dwarfism candidate.</li>
<li>Nuvalent Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) stock gained 23.50% after the company <a href="https://www.benzinga.com//node/40865049" target="_blank" rel="noreferrer noopener">highlighted results for its ROS1 and ALK-Positive NSCLC programs</a> and accelerated its development timeline. The company also announced a $350 million public offering, and multiple firms raised their respective <a href="https://www.benzinga.com/quote/nuvl/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecasts on the stock</a>.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) stock gained 22.61% last week as stocks in the broader industrial space jumped following the Fed's announcement to cut rates by 50 basis points, which could support investment and economic growth.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) shares jumped 21.28%.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40972008/constellation-energy-li-auto-and-carvana-are-among-top-11-large-cap-gainers-last-week-sept-16-sept" target="_blank" rel="noreferrer noopener">Constellation Energy, Li Auto And Carvana Are Among Top 11 Large Cap Gainers Last Week (Sept 16-Sept 20): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40972060/novo-nordisk-chewy-and-fedex-are-among-top-10-large-cap-losers-last-week-sept-15-sept-21-are-the-o" target="_blank" rel="noreferrer noopener">Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

BLCO

EWTX

NUVL

POWL

Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock declined 23.61%. The company announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented <a href="https://www.benzinga.com//node/40873837" target="_blank" rel="noreferrer noopener">at the 2024 ESMO Annual Meeting</a>.</li>
<li>Joint Stock Company Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) stock tumbled 21.66% after Culper Research <a href="https://www.benzinga.com//node/40943334" target="_blank" rel="noreferrer noopener">issued a short report on the company</a>.</li>
<li>BioMarin Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) stock lost 16.74% last week <a href="https://www.benzinga.com//node/40885653" target="_blank" rel="noreferrer noopener">following strong dwarfism drug data</a> from rival Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>).</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) lost 13.26% <a href="https://www.benzinga.com//node/40961732" target="_blank" rel="noreferrer noopener">last week</a>.</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) stock fell 11.08% after the company reported worse-than-expected Q1 financial results and <a href="https://www.benzinga.com//node/40948046" target="_blank" rel="noreferrer noopener">cut FY25 guidance</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) stock decreased 9.01%. Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech received positive CHMP opinion for omicron KP.2-adapted <a href="https://www.benzinga.com//node/40956192" target="_blank" rel="noreferrer noopener">COVID-19 vaccine in the European Union</a>.</li>
<li>Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) stock fell 7.17%. Several analysts raised <a href="https://www.benzinga.com/quote/ajg/analyst-ratings" target="_blank" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares declined 6.97% after the company announced a selling stockholder&#8217;s public offering of shares <a href="https://www.benzinga.com//node/40949015" target="_blank" rel="noreferrer noopener">and a concurrent share repurchase</a>.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock fell 6.93% after <a href="https://www.benzinga.com//node/40961934" target="_blank" rel="noreferrer noopener">headline results from the mid-stage study</a> of monlunabant in obese patients.</li>
<li>Murphy USA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) shares fell 6.90% after JP Morgan downgraded the stock from Neutral to Underweight but raised its <a href="https://www.benzinga.com/quote/musa/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $415 to $435</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40972008/constellation-energy-li-auto-and-carvana-are-among-top-11-large-cap-gainers-last-week-sept-16-sept" target="_blank" rel="noreferrer noopener">Constellation Energy, Li Auto And Carvana Are Among Top 11 Large Cap Gainers Last Week (Sept 16-Sept 20): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?

Ascendis estimates the net proceeds from the offering will be approximately&nbsp;$281.3 million&nbsp;(assuming no exercise of the underwriters&#39; option to purchase additional ADSs), after deducting the underwriting commissions and estimated offering expenses. Ascendis intends to use the net proceeds of the offering to support the commercial preparations, launch and commercial activities, clinical development and regulatory approvals for its products and product candidates, and for working capital and general corporate purposes.

Reported Earlier, Ascendis Pharma Prices $281.3M Public Offering Of 2M ADSs At $150/ADS

All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional&nbsp;$45 million of ADSs at the public offering price, less the underwriting commissions.&nbsp;

Offerings

Ascendis Pharma Commences Public Offering Of $300M Of ADSs

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $264 to $289.

Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $289

Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and raises the price target from $178 to $207.

Citigroup Maintains Buy on Ascendis Pharma, Raises Price Target to $207

Ascendis Pharma ticks higher amid chatter it cancelled from upcoming conference

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 10/21/2024, According to Top Analysts

TD Cowen raised the firm's price target on Ascendis Pharma (ASND) to $160 from $157 and keeps a Buy rating on the shares. The firm updated its mode...

Ascendis Pharma price target raised to $160 from $157 at TD Cowen

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price t...

Morgan Stanley Reaffirms Their Hold Rating on Ascendis Pharma (ASND)

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $167.00....

Morgan Stanley Keeps Their Hold Rating on Ascendis Pharma (ASND)

Cantor Fitzgerald analyst Olivia Brayer lowered the firm's price target on BioMarin (BMRN) to $90 from $110 and keeps an Overweight rating on the s...

BioMarin price target lowered to $90 from $110 at Cantor Fitzgerald

Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an exclusive worldwide license to the TransCon technology platform to devel...

Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform

In a report released today, Li Watsek from Cantor Fitzgerald maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a price targ...

Ascendis Pharma (ASND) Receives a Buy from Cantor Fitzgerald

Novo Nordisk, Ascendis partner to advance once-monthly obesity drug candidate

How does Viking's weight loss med compare to ones from Novo, Eli Lilly?

CDNS

TSX:ADYA

VKTX

Financing

Press Releases

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Legal

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

Comments

Ascendis Pharma

Actualités

Dernières nouvelles pour Ascendis Pharma (NASDAQ:ASND) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL